High-dose rituximab and anti-MAG–associated polyneuropathy
- 14 March 2006
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 66 (5), 742-744
- https://doi.org/10.1212/01.wnl.0000201193.00382.b3
Abstract
Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.Keywords
This publication has 9 references indexed in Scilit:
- Extended rituximab therapy in Waldenström's macroglobulinemiaAnnals Of Oncology, 2005
- Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIgNeurology, 2004
- Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximabNeurology, 2003
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodiesMuscle & Nerve, 2003
- IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using RituximabNeurology, 1999
- RituximabDrugs, 1999
- Electrophysiological monitoring in clinical trialsMuscle & Nerve, 1998
- Demyeliating neuropathy and monoclonal IgM antibody to myelin‐associated glycoproteinNeurology, 1983